BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events.

Finally, we take the discussion back to the clinic, and consider how we might deploy anti-BCMA therapies most effectively for our patients. We consider the sequencing of treatment, and what further evidence is needed to more fully inform our therapy decisions.